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ABSTRACT 
Objective: The present work aimed to develop a simple, rapid, specific and precise ultra-performance liquid chromatography-tandem mass 
spectrophotometric (LC–MS/MS) validated method for quantification of sofosbuvir and internal standard (ISTD) Sofosbuvir-d3 in human plasma. 
Methods: Samples prepared by employing liquid-liquid extraction (LLE) using 2.5 ml of ethyl acetate. Chromatographic separation was achieved on 
Gemini 5µ C18, 50 x 4.6 mm column using a mixture of 0.1% (v/v) formic acid in water to methanol at a ratio of 30:70 v/v as the mobile phase. The flow 
rate was 0.50 ml/min. The LC eluent was split, and approximately 0.1 ml/min was introduced into Tandem mass spectrometer using turbo Ion Spray 
interface at 325 °C. Quantitation was performed by transitions of 428.35/279.26 (m/z) for sofosbuvir and 431.38/282.37 (m/z) for sofosbuvir-d3. 
Results: The concentrations of ten working standards showed linearity between 4.063 to 8000.010ng/ml (r2 ≥ 0.9985). Chromatographic 
separation was achieved within 2 min. The average extraction recoveries of three quality control concentrations were 75.36% for sofosbuvir and 
were within the acceptance limits. The coefficient of variation was ≤15% for intra-and inter-batch assays. The %CV of ruggedness ranges 0.35% and 
3.09%. The % stability of short term and long term stock solution stability studies was found to be 97.25% and 98.81% respectively.  
Conclusion: The results obtained for specificity, linearity, accuracy, precision, ruggedness and stability studies were within the acceptance limits. 
Thus the validated economical method was applied for pharmacokinetic studies of sofosbuvir. 
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INTRODUCTION 
Sofosbuvir, a phosphoramidate prodrug, is chemically described as 
(S)-Isopropyl 2-((S) ((2R, 3R, 4R, 5R)-5-(2, 4-dioxo-3,4-dihydro-
pyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4 methyl tetrahydrofuran-
2-yl) methoxy)-(phenoxy) phosphorylamino) propanoate [1-2]. 
Literature survey reveals two HPLC methods for determination of 
sofosbuvir from its bulk and pharmaceutical dosage forms [3-4]. 
Three UPLC-MS/MS method were reported for quantification of 
sofosbuvir from its metabolites and along with other drugs from 
human plasma [5-7]. Described here is a simple, sensitive, and 
selective UPLC-MS/MS method for sofosbuvir in the human plasma 
concentration range of 4.063 to 8000.010ng/ml. As there is no 
literature on stability and validation details of sofosbuvir estimation 
from human plasma, this study performed assay validations, 
according to the FDA guidelines [8]. While this method with 
validation details were economical and applied for pharmacokinetic 
studies of sofosbuvir. 
MATERIALS AND METHODS [5] 
Apparatus and software 
The UPLC (Waters, Model Acquity) was coupled with Mass 
spectrometer (Waters Quattro Premier XE) having Turbo Ion Spray 
(Waters Quattro Premier XE). The chromatographic integration was 
performed by MassL ynx V4.1 software. 
Chemicals and reagents 
Sofosbuvir and Sofosbuvir-d3 (IS) were procured from Mylan 
Laboratories Ltd, Hyderabad, Formic acid, Methanol and ethyl 
acetate was procured from Merck Specialities Pvt. Ltd, Mumbai, 
India. Water used was collected from water purification systems 
(Milli Q, MilliPore, USA) installed in the laboratory. Pooled drug-free 
expired frozen human plasma (K2-EDTA as anticoagulant) was 
obtained froma Blood Bank, Hyderabad, was used during validation 
and study sample analysis. The plasma was stored into-70±5 °C. 
Standards and working solutions 
Calibration standard solutions 
Stock solutions of sofosbuvir and Sofosbuvir-d3 internal standard 
(IS) were prepared in methanol. Further dilutions were carried out 
in 50% methanol. Calibration standards often concentration levels 
were prepared freshly by spiking drug-free plasma with a sofosbuvir 
stock solution to give the concentrations of 4.063, 8.125, 62.5, 125.0, 
250, 500, 1000, 2000, 4000 and 8000ng/ml. 
Quality control standards 
Lowest quality control standards, Median quality control standards 
and highest quality control standards were prepared by spiking 
drug-free plasma with sofosbuvir to give a solution containing 
11.488, 522.180 and 7252.503 ng/ml respectively. They were stored 
at-20 °C till the time analysed. 
Chromatographic conditions 
Chromatographic separation was performed on Gemini 5µ C18, 50 x 4.6 
mm, analytical column and the mobile phase was a mixture of 0.1% 
(v/v) formic acid in water to methanol at a ratio of 30:70 v/v. Injection 
volume was 10μL. The flow rate was 0.50 ml/min. Total analysis time of 
single injection was 2.0 min. Column oven temperature and autosampler 
temperature was set to 30 °C and 10 °C, respectively. 
Mass spectrometric conditions 
The LC eluent was split, and approximately 0.100 ml/min was 
introduced via electrospray ionisation using a Turbo Ion Spray 
interface set at 325 °C to generate positive ions [M+H]+. The Mass 
spectrometric parameters were optimised as shown in table no 1. 
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Table 1: Mass spectrometric conditions 
Capillary voltage 3500V 
Nozzle voltage 1500V 
Delta EMV(+) 500 Positive 
Gas flow 5 L/min 
Gas temperature 350 °C 
Nebulizer pressure 25 psi 
Sheath gas temperature 300 °C 
Sheath gas flow 11L/min 
Acquisition 
Parameters Sofosbuvir ISTD  
Transition 428.35/279.26 (m/z) 431.38/282.37 (m/z) 
Polarity Positive Positive 
MS1 resolution Unit Unit 
MS2 resolution Unit Unit 
Dwell time (millisec) 200 200 
Fragmentor (V) 100 100 
Collision energy (V) 8 10 
 
Sample preparation method 
To 250 µl of plasma, 50 µl of ISTD (1µg/ml) and 50 µl of 0.1% formic 
acid was added and vortexed. The drug was extracted with 2.5 ml of 
ethyl acetate, followed by centrifugation at 2000 rpm/min on a 
cooling centrifuge for 15 min at 4 °C. The supernatant of 2 ml was 
withdrawn and evaporated at 50 °C 15 psi of nitrogen until dryness 
at LV evaporator. The residue was reconstituted with 500 µl of 
mobile phase, and respective samples were injected into the column. 
Validation [9-13] 
Specificity 
A solution containing 4.063ng/ml was injected onto the column 
under optimised chromatographic conditions to show the 
separation of sofosbuvir from impurities and plasma. The specificity 
of the method was checked for the interference from plasma. 
Linearity 
Spiked concentrations were plotted against peak area ratios of 
sofosbuvir to the internal standard and the best fit line was 
calculated. Wide range calibration was determined by solutions 
containing4.063 to 8000.010ng/ml. 
Recovery studies 
The % mean recoveries were determined by measuring the 
responses of the extracted plasma Quality control samples at HQC, 
MQC and LQC against un-extracted Quality control samples at HQC, 
MQC and LQC. 
Precision and accuracy 
The between-run (Inter-day) accuracy and precision evaluation 
were assessed by the repeated analysis of human K3 EDTA plasma 
samples containing different concentrations of sofosbuvir on 
separate occasions. A single run consisted of a calibration curve plus 
six replicates of the lower limit of quantitation, low, medium and 
high-quality control samples. 
Within-run (Intraday) accuracy and precision evaluations were 
performed by analysing replicate concentrations of sofosbuvir in 
human K3 EDTA plasma. The run consisted of a calibration curve 
plus a total of 24 spiked samples, six replicates of each of the LLOQ, 
lower, medium and higher quality control samples. 
Matrix effect 
The matrix effect for the intended method was assessed by using 
chromatographically screened human plasma. Concentrations 
equivalent to LLOQ of Sofosbuvir were prepared with seven 
different plasma batches/lots. Samples were analysed along with 
one set of freshly spiked CC Standards prepared in the screened 
biological matrix. 
Ruggedness 
The ruggedness of the method was assessed by analysing a precision 
and accuracy batch using a different column, by the different analyst 
in another instrument. 
Stability studies 
Short-term stock solution stability of sofosbuvir 
Solutions of sofosbuvir were prepared in methanol (Stability 
Samples) and were kept at room temperature for 6 h 30 min. A 
freshly prepared solution of sofosbuvir (Comparison Samples) and 
stability samples were diluted at approximately the same analyte 
concentration and analysed in a single run; analyte responses were 
used to determine % stability over time. 
Short-term stock solution stability of internal standard 
Solutions of internal standard (Sofosbuvir-d3) were prepared in 
methanol (Stability Samples) and were kept at room temperature 
for 6 h 30 min. A freshly prepared solution of internal standard 
(Comparison Samples) and stability samples were diluted at 
approximately the same analyte concentration and analysed in a 
single run; Analyte responses were used to determine % stability 
over time. 
Long-term stock solution stability of sofosbuvir 
Solutions of Sofosbuvir were prepared in methanol (Stability 
Samples) and were kept at refrigerator (2-8 °C) for 10 D 02 H. A 
freshly prepared solution of sofosbuvir (Comparison Samples) and 
stability samples were diluted at approximately the same analyte 
concentration and analysed in a single run. 
Long-term stock solution stability of internal standard 
Solutions of Internal standard were prepared in methanol (Stability 
Samples) and were kept at refrigerator (2-8 °C) for 10 D 02 H. A 
freshly prepared solution of internal standard (Comparison 
Samples) and stability samples were diluted at approximately the 
same analyte concentration and analysed in a single run. 
Freeze-thaw stability 
Samples were prepared at low and high-quality control levels, 
aliquoted and frozen at-70 °C. Some of the aliquots of quality control 
samples were subjected to five freeze-thaw cycles (stability 
samples). A calibration curve and quality control samples were 
freshly prepared (Comparison Samples) and processed with 6 
replicates of stability samples and analysed in a single run. 
RESULTS AND DISCUSSION 
The chromatography observed during the course of validation was 
acceptable and representative chromatograms of standard blank, 
HQC, MQC, LQC and LLOQ are shown in fig. 1-3. 
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Fig. 1: Chromatograms of standard blank and HQC matrix 
 
 
Fig. 2: Chromatograms of MQC and LQC 
 
 
Fig. 3: Chromatograms of LLOQ 
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The method developed was validated for specificity, accuracy and 
precision, linearity, ruggedness and stability as per FDA guidance [9-
11]. The results of validating parameters are given below. 
Specificity 
Nine different lots of plasma were analysed to ensure that no 
endogenous interferences were present at the retention time of 
sofosbuvir and Sofosbuvir-d3. Nine LLOQ (4.063 ng/ml) level 
samples along with plasma blank from the respective plasma lots 
were prepared and analysed. (table 2). In all plasma blanks, the 
response at the retention time of sofosbuvir was less than 20% of 
LLOQ response and at the retention time of IS, the response was less 
than 5% of mean IS response in LLOQ. The typical chromatogram of 
plasma blank and the chromatogram of LLOQ was shown in (fig. 1). 
 
Table 2: Results of specificity for sofosbuvir and sofosbuvir-d3 (ISTD) 
S. No. Drug response ISTD response 
STD BL  LLOQ % Interference STD BL  LLOQ % Interference 
Area RT Area RT 
01 0 298 0.800 NIL 0 61776 0.800 NIL 
02 0 290 0.800 NIL 0 66613 0.800 NIL 
03 0 334 0.800 NIL 0 70621 0.800 NIL 
04 0 267 0.807 NIL 0 64807 0.800 NIL 
05 0 271 0.800 NIL 0 67694 0.800 NIL 
06 0 303 0.800 NIL 0 65249 0.800 NIL 
07 0 281 0.800 NIL 0 68774 0.800 NIL 
08 0 255 0.800 NIL 0 62927 0.800 NIL 
09 0 147 0.800 NIL 0 37012 0.800 NIL 
10 0 283 0.800 NIL 0 66641 0.800 NIL 
 
Linearity 
The calibration curve (peak area ratio Vs Concentration) was 
linear over working range of 4.063 to 8000.010ng/ml with ten 
point calibration used for quantification by linear regression, 
shown in (fig. 2). The regression equation for the analysis was 
Y=0.0011227x-0.000164437 with coefficient of correction (r2) = 
0.9985. 
Recovery 
The % mean recovery for sofosbuvir in LQC, MQC and HQC was 
75.47%, 74.37% and 76.26% respectively (table 3). 
 
 
Fig. 3: Spiked concentrations (4.063 to 8000.010ng/ml) were plotted against calculated concentration Vs concentration with ten point 
calibration used for quantification by linear regression 
 
Table 3: The % mean recovery of sofosbuvir for LQC, MQC and HQC 
S. No. HQC MQC LQC 
Aqueous  
area ratio 
Extracted area 
ratio 
Aqueous area 
ratio 
Extracted area 
ratio 
Aqueous area 
ratio 
Extracted area 
ratio 
01 13.466 8.226 0.981 0.598 0.021 0.013 
02 13.541 8.082 1.010 0.590 0.022 0.013 
03 13.318 7.995 0.995 0.571 0.021 0.012 
04 13.133 8.248 1.001 0.599 0.021 0.013 
05 12.997 7.994 0.985 0.600 0.021 0.013 
Mean 13.2910 8.1090 0.9944 0.5916 0.0212 0.0128 
SD 0.22652 0.12243 0.01178 0.01218 0.00045 0.00045 
% CV 1.70 1.51 1.18 2.06 2.11 3.49 
% Mean Recovery 76.26 74.37 75.47 
%Global Recovery  75.36  
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Intraday (within run) and Inter-day (between run) precision 
and accuracy 
The within-run coefficients of variation ranged between 1.06% and 
5.06% for sofosbuvir. The within-run percentages of nominal 
concentrations ranged between 97.21% and 105.93% for 
sofosbuvir. Results are presented in table 4. 
The between-run coefficients of variation ranged between 2.04% 
and 5.48% for sofosbuvir. The between-run percentages of nominal 
concentrations ranged between 98.34% and 100.58% for 
sofosbuvir. Results are presented in table 4. 
Matrix effect 
The % accuracy of LLOQ samples prepared with the different biological 
matrix lots were found within the range of 89.49 to 97.49% which were 
found within the range of 80.00-120.00% for the seven different plasma 
lots. % CV for LLOQ samples was observed as 2.87% which are within 
20.00% of the acceptance criteria. Results are presented in table 5. 
 
Table 4: Intraday and interday precision and accuracy 
QC ID HQC MQC LQC LLOQ QC 
Concentration (ng/ml) 7252.503 522.180 11.488 4.136 
Within Batch Precision and Accuracy 
PandA I Calculated Concentration (ng/ml) 
6910.342 511.080 11.630 4.290 
7009.484 518.984 10.484 3.998 
7189.506 514.176 11.501 4.116 
7156.740 511.840 11.892 4.132 
6984.985 504.031 11.887 4.477 
Mean 7050.211 512.0222 11.4788 4.2026 
 SD 118.5622 5.42876 0.58102 0.18526 
% CV 1.68 1.06 5.06 4.41 
% Mean Accuracy 97.21 98.05 99.92 101.61 
PandA II 7234.610 533.688 12.086 4.263 
7192.185 531.929 12.605 4.266 
7272.508 523.890 12.009 4.246 
7351.433 522.452 11.705 4.070 
7380.960 535.319 12.440 4.172 
Mean 7286.339 529.4556 12.1690 4.2034 
 SD 78.93435 5.88296 0.35753 0.08377 
% CV 1.08 1.11 2.94 1.99 
%  
Mean Accuracy 
100.47 101.39 105.93 101.63 
PandA III 7161.887 520.892 11.414 4.123 
7036.505 514.024 11.006 4.395 
6960.208 497.103 10.554 4.354 
7181.121 521.290 11.095 4.168 
6960.064 522.273 11.006 4.342 
Mean 7059.957 515.1164 11.0150 4.2764 
 SD 106.7109 10.58730 0.30752 0.12214 
% CV 1.51 2.06 2.79 2.86 
% Mean Accuracy 97.35 98.65 95.88 103.39 
Between Batch Precision and Accuracy 
Mean 7132.169 518.8647 11.5543 4.2275 
 SD 147.64818 10.58931 0.63313 0.13174 
% CV 2.07 2.04 5.48 3.12 
% Mean Accuracy 98.34 99.37 100.58 102.21 
 
Table 5: Results of matrix effect 
LLOQ nominal concen (4.063ng/ml)  
S. No. Calculated LLOQ  concn (ng/ml) % accuracy 
1 3.937 96.9 
2 3.808 93.73 
3 3.823 94.09 
4 3.961 97.49 
5 3.636 89.49 
6 3.867 95.17 
7 3.766 92.69 
  % Mean accuracy 94.223 
   SD 2.7003 
  % CV 2.87 
 
Ruggedness 
The coefficients of variation ranged between 0.35% and 3.09% for 
sofosbuvir. The percentages of nominal concentrations ranged between 
93.2% and 99.29% for sofosbuvir. Results are presented in table 6. 
Stability studies 
Short-term stock solution stability of sofosbuvir and internal 
standard 
Sofosbuvir and internal standard were found to be stable in 
methanol for 6 h 30 min at room temperature with a % stability of 
97.25% and 97.0% respectively. Results are presented in table 7. 
Long-term stock solution stability of sofosbuvir and internal 
standard 
Sofosbuvir and internal standard were found to be stable in 
methanol 10 D 02 H at refrigerator (2-8 °C) with a % stability of 
98.81% and 107.96% respectively. Results are presented in table 8. 
Freeze-thaw stability 
Sofosbuvir is found to be stable in human K3 EDTA plasma after five 
freeze-thaw cycles at-70 °C with coefficients of variation of 3.27% 
(LQC) and 3.86% (HQC) for sofosbuvir, and the percentages of 
nominal concentrations for sofosbuvir were found to be 103.17% 
(LQC) and 101.23% (HQC). Results are presented in table 9. 
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Table 6: Results of ruggedness with different column 
QC ID HQC MQC LQC LLOQ QC 
Conc.(ng/ml) 7252.503 522.180 11.488 4.136 
PandA ID  Calculated concentration (ng/ml) 
Different  
Column 
Acquisition batch ID: 031008PandADC01 
6980.672 523.650 11.419 4.044 
7005.431 518.262 11.463 3.725 
7243.518 521.038 11.403 3.853 
7100.206 527.007 11.307 3.861 
7312.115 516.714 11.443 3.790 
Mean 7128.3884 521.3342 11.4070 3.8546 
 SD 145.55342 4.13570 0.06040 0.11925 
% CV 2.04 0.79 0.53 3.09 
% Mean Accuracy 98.29 99.84 99.29 93.20 
 
Table 7: Short-term stock solution stability of drug and ISTD 
S. NO. Drug ISTD 
Nominal Conc (ng/ml) Nominal Conc (µg/ml) 
396675.19 400000.4 4.034 4.075 
Area ratio Area ratio 
comparison samples Stability samples Comparison samples Stability samples 
01 9.134 9.076 0.116 0.115 
02 9.181 8.829 0.117 0.114 
03 9.147 9.090 0.115 0.117 
04 9.082 8.973 0.117 0.113 
05 9.231 8.946 0.114 0.111 
06 9.197 8.996 0.117 0.112 
Mean 9.1620 8.9850 0.1160 0.1137 
SD 0.05245 0.09532 0.00126 0.00216 
% CV 0.57 1.06 1.09 1.90 
% Mean Stability 97.25 97.00 
 
Table 8: Long-term stock solution stability of drug and internal standard 
S. No. DRUG ISTD 
Nominal Conc (ng/ml) Nominal Conc (µg/ml) 
400000.480 398186.240 4.214 4.075 
Area ratio Area ratio 
Comparison samples Stability samples Comparison samples Stability samples 
01 9.219 9.049 0.108 0.111 
02 9.116 9.111 0.107 0.110 
03 9.228 9.026 0.108 0.115 
04 8.918 9.141 0.112 0.119 
05 9.208 9.073 0.111 0.119 
06 9.138 9.022 0.113 0.114 
Mean 9.1378 9.0703 0.1098 0.1147 
SD 0.11700 0.04777 0.00248 0.00383 
% CV 1.28 0.53 2.26 3.34 
% Mean Stability 98.81 107.96 
 
Table 9: Freeze-thaw stability at-70 °C 
S. No. HQC   LQC   
Nominal Conc (ng/ml)    Nominal Conc (ng/ml)   
7252.503   11.488   
Calculated Conc (ng/ml) % accuracy Calculated Conc (ng/ml) % accuracy 
1 7255.363 100.04 11.571 100.72 
2 6985.35 96.32 11.547 100.51 
3 7017.724 96.76 12.168 105.92 
 
CONCLUSION 
Chromatographic separation was performed on Gemini 5µ C18, 50 x 4.6 
mm, analytical column and the mobile phase was a mixture of 0.1% 
(v/v) formic acid in water to methanol at a ratio of 30:70 v/v. The drug 
was extracted from the sample with 2.5 ml of ethyl acetate. The 
specificity of the method was checked for the interference from plasma. 
Wide range calibration was determined by solutions containing 4.063 to 
8000.010ng/ml. The % mean recovery for sofosbuvir in LQC, MQC and 
HQC was 75.47%, 74.37% and 76.26% respectively. The within-run 
coefficients of variation ranged between 1.06% and 5.06% for 
sofosbuvir. The between-run coefficients of variation ranged between 
2.04% and 5.48% for sofosbuvir the % accuracy of LLOQ samples 
prepared with the different biological matrix lots were found within the 
range of 89.49 to 97.49%. Stability test were performed to assess the 
long term and short term stability of sofosbuvir sample solutions, 
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internal standard solutions. The developed method was validated for the 
quantitative determination of sofosbuvir from plasma was simple, rapid, 
specific, sensitive, accurate and precise. Hence, the method is quite 
suitable to detect the drug from plasma samples of human volunteers. 
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